Results 91 to 100 of about 658,898 (341)

Factors Influencing Immunization Status in Primary Care Clinics

, 2002
Background and Objectives: National standards and goals for childhood immunization rates are well established. Yet, despite clear standards and goals, physicians do not achieve the desired rate (90%) for immunization coverage. This study examined factors
Dailey, Amy B., Meires, Jan, Page, David
core  

Has VZV epidemiology changed in Italy? Results of a seroprevalence study [PDF]

, 2017
The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era.
Amodio E., Angelillo I., Bagordo F., Baldo V., Baldovin T., Bandettini R., Bassetti D., Bassi C., Bella A., Bernardini S., Binda S., Bonanni P., Bordonaro P., Brignole G., Cacello E., Caligiuri P., Casalino P., Castiglia P., Cia M., Cicerchia E., Clerico L., Cracchiolo M., D'Agaro P., De Donno A., Del Manso M., Devoti G., Di Giuseppe G., Ditommaso S., Fazii P., Gabutti G., Gallo T., Gamper A., Giandomenico A. M., Giraldi C., Grasso G., Greco F., Guerra G., Guido M., Idolo A., Kuhdari P., Lupi S., Maglione F., Manchia P., Megha M., Pagani E., Passamonti B., Pellegrinelli L., Pelliccioni A. R., Perrone M., Peruzzi M., Piana A., Primache V., Renzoni C., Resciniti C., Romano P., Rossi P., Rota M. C., Sammarco M. L., Schettini S., Schippa S., Sciuto V., Segat L., Stefanati A., Sticchi L., Tiscione E., Trucchi C., Tumolo M. R., Vallerini M., Vargiu P., Vitale F., Zizza A., Zotti C.   +71 more
core   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Exploring the Causes of Low Immunization Status in School Going Children [PDF]

, 2012
Background: Although a definitive immunization program has been advocated for children in our country, the immunization coverage is far from satisfactory. There is paucity of survey studies related to immunization pattern.
Inamdar, M, Inamdar, S, Piparsania , S, Singh, K   +3 more
core   +1 more source

TREM2 Drives Neutrophil Extracellular Traps‐Induced Dendritic Cell Maturation and Contributes to Lupus Progression

Advanced Science, EarlyView.
TREM2 recognizes NETs‐derived MPO to promote DC maturation and antigen presentation, thereby exacerbating the autoimmune response in SLE. Mechanistically, TREM2 activation triggers the DAP12/SYK/ERK cascade and enhances NETs internalization by DCs, which in turn activates the cGAS/STING signaling pathway.
Jingxian Shu, Jiabi Liang, Linda Zeng, Shuping Zhong, Xueling Fang, Yating Xu, Yongjian Wu, Xi Huang   +7 more
wiley   +1 more source

Selective Use of the Executive Immunity Power: A Denial of Due Process? [PDF]

, 1980
Attacks on the government\u27s power to grant immunity to cooperative witnesses have been premised on several grounds, including the due process clause of the fifth amendment.
Schwartz, Howard
core   +1 more source

Immunization of Real Complex Communication Networks [PDF]

, 2005
Most communication networks are complex. In this paper, we address one of the fundamental problems we are facing nowadays, namely, how we can efficiently protect these networks.
Echenique, Pablo, Gomez-Gardenes, Jesus, Moreno, Yamir   +2 more
core   +6 more sources

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

Advanced Science, EarlyView.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong, Fang Liu, Dawei Wang, Yanfen Li, Man Zhang, Yuting Zhou, Gengshen Song   +6 more
wiley   +1 more source

Vaccines: Propaganda and Practice [PDF]

, 2008
Vaccines are a cost effective, time tested means of reducing morbidity and mortality. As more and more new vaccines are introduced and more diseases come under the purview of ‘vaccination net’, the routine immunization program is sidelined.\ud This is ...
Baliga, Shantharam B, Baliga, Shrikala
core   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source